Skip to main content

Table 5 Secondary outcomes, clinical outcomes

From: Effects of a pharmaceutical care intervention on clinical outcomes and patient adherence in coronary heart disease: the MIMeRiC randomized controlled trial

Categorical variables

Intervention group (n = 159)

Control group (n = 157)

Risk difference, % (95% CI)

P

Systolic blood pressure < 140 mm Hg, n (%)

66 (59.5)

63 (58.3)

1.1 (-11–9 to 14.2)

.865

 Eligible participants, n

111

108

  

Unplanned healthcare contact, n (%)

22 (14.5)

14 (9.0)

5.4 (-1.7 to 12.6)

.138

 Eligible participants, n

152

155

  

Continuous variables, mean (SD)

  

B (95% CI)

P

HeartQoL physical score

2.3 (0.7)

2.3 (0.7)

0.044 (-0.080 to 0.169)

.485

HeartQoL emotional score

2.5 (0.6)

2.4 (0.7)

-0.002 (-0.126 to 0.121)

.970

 Eligible participants, n

124

136

  
  1. B, unstandardized coefficient; HeartQoL, Heart quality of life instrument; n, number; SD, standard deviation